This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
The approval of tirzepatide, the first dual incretin agonist, for the treatment of type 2 diabetes ushered in a “new
In type 2 diabetes, ARMMS-T2D is the largest and longest-running comparison of metabolic surgery versus medical and lifestyle intervention. In